It’s an inescapable fact that drug development costs money. Current estimates suggest that its costs are spiralling towards US$1 billion for just one cancer drug to make the journey from a twinkle in a scientist’s eye to a treatment in the clinic.
But as well as being an expensive time for drug development, it’s also an exciting one. We are now witnessing a wave of ‘next-generation’ drugs, specifically designed to hit biological targets in cancer cells while leaving healthy tissues unharmed.
But given the costs of developing drugs, hard decisions need to be made. Pharmaceutical companies may develop many chemical compounds with interesting anti-cancer properties, but even the biggest don’t always have the resources to develop them all further. This means that potentially life-saving drugs end up stuck gathering dust on their shelves.
Posted by Kat Arney 
Welcome to the
